



Effects of intraoperative or postoperative administration of intravenous iron supplements on hemoglobin recovery in patients with total knee arthroplasty

A systematic review and meta-analysis

Sang Gyu Kwak, PhDa, Jae Bum Kwon, MDb, Jin Woo Bae, MDb, Dong Jin Bae, MDb, Dong Kun Kim, Studentc, Won-Kee Choi, MDb,* ©

Abstracts

Background: The objectives of the researchers are as follows: First, to investigate whether intraoperative or postoperative administration of Intravenous (IV) iron supplements in patients undergoing primary total knee arthroplasty (TKA) can contribute to the hemoglobin recovery during the postoperative period (between 4 and 8 weeks after surgery). Second, to examine whether the administration of IV iron supplements during or immediately after TKA in patients undergoing primary TKA can reduce the need for allogenic blood transfusion during hospitalization.

Methods: Articles published between January 1, 1990, and June 30, 2023 were searched in PubMed, Cochrane, and Embase. The population, intervention, comparison, and outcome of this study are as follows; Population: Patients undergoing primary total knee arthroplasty; Intervention: Administration of IV iron supplements during or immediately after surgery; Comparison: Non-administration of IV iron supplements; Outcome: Degree of hemoglobin recovery (between 4 and 8 weeks after surgery) and the need for blood transfusion during hospitalization.

Results: There was a statistically significant difference in the amount of change in hemoglobin between iron supplementation group and non-iron supplementation group. The effect size were -0.44 (95% confidence interval: -0.69 to -0.19, P value < .001) in all patients. This means that the amount of change in hemoglobin were significantly reduced in the iron supplementation group than in the non-iron supplementation group. There was a statistically significant difference for post-operative transfusion rate between 2 groups. The effect size were 0.28 (95% confidence interval: 0.10-0.81, P value = .02) in all patients. This means that the post-operative transfusion rate was significantly less in the iron supplementation group than in the non-iron supplementation group

Conclusion: The administration of IV iron supplements during or after TKA surgery increases hemoglobin recovery between 4 and 8 weeks after surgery and reduces the need for allogeneic blood transfusion during hospitalization.

Abbreviations: CI = confidence interval, IV = Intravenous, TKA = total knee arthroplasty.

Keywords: total knee arthroplasty, iron, hemoglobin, transfusion

1. Introduction

Total knee arthroplasty (TKA) is one of the surgeries associated with high blood loss. [1] The frequency of allogeneic blood transfusion after surgery among different institutions varies from 3% to 69%. [2,3] Surgeons performing TKA make various

efforts to reduce blood transfusions and minimize their associated complications. [4] One method of reducing allogenic blood transfusions is by promoting the recovery of hemoglobin levels in patients. The administration of intravenous (IV) iron supplements is one of the commonly used approaches to enhance hemoglobin recovery. [5,6] Traditionally, IV iron

This research was supported by a grant of Daegu Catholic Medical University Student Research Program (2023).

The authors have no funding and conflicts of interest to disclose.

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

How to cite this article: Kwak SG, Kwon JB, Bae JW, Bae DJ, Kim DK, Choi W-K. Effects of intraoperative or postoperative administration of intravenous iron supplements on hemoglobin recovery in patients with total knee arthroplasty: A systematic review and meta-analysis. Medicine 2023;102:43(e35744).

Received: 30 July 2023 / Received in final form: 20 September 2023 / Accepted: 29 September 2023

http://dx.doi.org/10.1097/MD.0000000000035744

^a Department of Medical Statistics, College of Medicine, Daegu Catholic University, Daegu, Korea, ^b Department of Orthopaedic Surgery, College of Medicine, Daegu Catholic University, Daegu, Korea, ^c College of Medicine, Daegu Catholic University, Daegu, Korea.

^{*} Correspondence: Won-Kee Choi, Department of Orthopaedic Surgery, College of Medicine, Daegu Catholic University, 3056-6, Daemyung-4-dong, Nam-gu, Daegu, Korea (e-mail: cwk1009@hanmail.net).

supplements are administered in the outpatient setting before surgery, as it takes approximately 2 weeks for hemoglobin levels to recover.^[7-9] Previous studies have investigated the effects of preoperative IV iron supplementation on hemoglobin recovery.^[10] However, due to the difficulty of additional outpatient visits for IV iron supplementation, there has been an increasing trend in administering IV iron supplements during or immediately after TKA, and research results on this approach have also been reported.

Therefore, the authors aim to analyze the existing research on whether intraoperative or postoperative administration of IV iron supplements can facilitate hemoglobin recovery and reduce the need for blood transfusion in patients undergoing primary TKA.

The objectives of the researchers are as follows: First, to investigate whether intraoperative or postoperative administration of IV iron supplements in patients undergoing primary TKA can contribute to the hemoglobin recovery during the postoperative period (between 4 and 8 weeks after surgery). Second, to examine whether the administration of IV iron supplements during or immediately after TKA in patients undergoing primary TKA can reduce the need for allogenic blood transfusion during hospitalization.

2. Methods

This study is not a clinical study for humans, a protocol for obtaining IRB approval has not been written. However, the protocol necessary to carry out this study was written, and the contents of the protocol were described throughout the paper. We have registered on the International prospective register of systematic reviews site (https://www.crd.york.ac.uk/PROSPERO/) and the ID is 448010.

2.1. Search strategy

The population, intervention, comparison, and outcome of this study are as follows.

- (1) Population: Patients undergoing primary total knee arthroplasty.
- (2) Intervention: Administration of IV iron supplements during or immediately after surgery.
- (3) Comparison: Non-administration of IV iron supplements.
- (4) Outcome: Degree of hemoglobin recovery (between 4 and 8 weeks after surgery) and the need for blood transfusion during hospitalization.

Articles published between January 1, 1990, and June 30, 2023 were searched in PubMed, Cochrane, and Embase using the following key phrases (Table 1).

2.2. Inclusion and exclusion criteria

The following studies were included in this study:

- (1) Studies involving patients undergoing primary total knee arthroplasty and receiving intraoperative or postoperative administration of IV iron supplements.
- (2) Studies comparing the intervention group (administration of IV iron supplements during or immediately after surgery) with a control group (no administration of IV iron supplements).
- (3) Studies written in English.

The exclusion criteria were as follows:

- (1) Review articles, case reports, protocols, and conference presentations.
- (2) Studies involving patients undergoing primary total knee arthroplasty who received preoperative administration of IV iron supplements.

Table 1

Articles were searched in PubMed using the following key phrases.

<i>j</i> 1, 2023
Query
"Total knee arthroplasty" [Ti/Ab] or
"Total knee replacement" [Ti/Ab] or
"Arthroplasty" [Ti/Ab]
"Ferrous" [Ti/Ab] or
"Ferric" [Ti/Ab] or
"Iron" [Ti/Ab]
#1 and # 2

2.3. Data extraction

Data for meta-analysis were independently investigated by 2 researchers (W.K.C. and S.G.K.). Duplicate studies were excluded, and studies that met the eligibility criteria were selected. Studies were evaluated for eligibility by reviewing the title and abstract. After reading the full-text, studies were finally selected for inclusion in the meta-analysis, and discrepancies were resolved through discussion. Study design, intervention, treatment timing, number of patients (intervention and control groups), operation, outcome measurements and time of hemoglobin measurements were investigated.

Outcome variables were the degree of hemoglobin recovery after surgery (between 4 and 8 weeks after surgery) and the presence or absence of blood transfusion during hospitalization. We collected the values of the evaluation variables such as the degree of hemoglobin recovery after surgery (4–8 weeks after surgery) and the presence or absence of blood transfusion presented in the paper according to the evaluation time points. Then, the amount of change from pre-operation to 4 to 8 weeks after surgery calculated. Since this corresponds to the amount of change in the dependent group, the mean value and standard deviation for change between pre-operation and post-operation were calculated using the following formulas and the correlation was derived from different study which presented the standard deviation for change.

$$Mean_{change} = Mean_{pre-op} - Mean_{post-op}$$
.

$$SD_{change} = \sqrt{SD_{pre-op}^2 + SD_{post-op}^2 - 2 \times Correlation \times SD_{pre-op} \times SD_{post-op}}$$

In some papers, while presenting an analysis using the data of the entire subject, at the same time, the results of the analysis using the data of patients with anemia and patients without anemia as a subgroup analysis were presented. Subgroup analysis results according to anemia were also collected.

2.4. Quality assessment

The quality assessment of risk of bias for the included studies was assessed using the Cochrane Collaboration's Handbook for randomized controlled trials. It was consisted of random sequence generation, allocation concealment, blinding of participants, incomplete outcome data, selective reporting, and other potential sources of bias. The judgments of bias were expressed as "low risk," "high risk," or "unclear risk." Quality assessment for retrospective studies was performed using the Newcastle–Ottawa quality assessment scale. It was consisted of selection, comparability and exposure. The questions in the selection part are composed of; Is case definition adequate; Representativeness of the cases; Selection of controls, and; Definition of controls, and each item can be evaluated with 1 star. The question in the comparability section is; Comparability of cases and controls on

the basis of the design or analysis and can be rated up to 2 stars. The questions in the exposure part consist of; Ascertainment of exposure; Same method of ascertainment for cases and controls, and; Nonresponse rate, and each question can be evaluated with 1 star. The Newcastle–Ottawa quality assessment scale can be evaluated by a total of 8 items and up to 9 stars.

2.5. Statistical analysis

RevMan v.5.3 software (http://tech.cochrane.org/revman) was used for statistical analysis of the pooled data. For each analysis, a heterogeneity test was performed using I^2 statistics, which measures the extent of inconsistency among results. P values of < .05 were considered as having substantial heterogeneity, and the random-effects model was used for analysis of the data. In contrast, when P values were \geq .05, pooled data was homogenous, and the fixed effects model was applied. We analyzed the mean difference between iron supplementation and non-iron supplementation. Further, the 95% confidence interval (CI) was used in the analysis. The effect size was calculated using mean

difference for hemoglobin recovery and odds ratio for blood transfusion. For the evaluation of publication bias, the funnel plot and the egger test were used. *P* value < .05 was considered statistically significant. For sensitivity analysis, RMSE (Root Mean Square Error) was calculated by using the effect size and total effect size calculated for each evaluation variable except for the I-th study. For RMSE calculation, the following formula was used.

$$RMSE = \sqrt{\frac{1}{k} \sum_{i=1}^{k} \left(Total \ effect \ size - Total \ effect \ size_{(i)} \right)^2}$$

For RMSE, closer to 0 means that the overall effect size is not sensitive to the study, and larger value means that the overall effect size is sensitive to the study.

3. Results

In the databases, 526 articles were searched, and 187 duplicated articles were removed (Fig. 1). After screening for




Figure 1. Flowchart showing the search results.

eligibility based on a review of the title and abstract, 29 articles were included for full-text reading. After a detailed assessment, 23 articles were excluded: 17 articles Included lower limb surgery other than TKA, and 6 articles included studies that used other drugs at the same time in addition to IV iron in the comparative analysis. Accordingly, 6 studies were finally included in our meta-analysis. [5,6,12–13] The characteristics of the studies included in the research also described in Table 2.

3.1. Study characteristics

As a result of reviewing title and abstracts, 2 RCT studies and 4 retrospective case-control studies were included. In the 6 studies, 784 participants for iron supplementation and 688 participants for non-iron supplementation. In all 6 studies, measurement of treatment effect was performed at 4 to 8 weeks after surgery.

There were 6 studies measuring Hgb and 5 studies measuring the post-operative transfusion rate.

3.2. Quality assessment

The results of a quality assessment using Newcastle–Ottawa quality assessment scale and Cochrane collaboration's handbook were presented in Table 3. Park et al (2021), Park et al (2022), Mamiar et al (2022), and Lee et al (2023) were case-control studies. Therefore, 4 studies were assessed using NOS. All then were rated 8 stars, which is considered as relatively high quality (selection: 4 stars; comparability: 2 stars; exposure: 2 stars). However, none of them mentioned a "nonresponse rate". Yoo et al (2021) and Choi et al (2022) were randomized controlled trials. Therefore, 2 studies were assessed the risk of bias based on the using and Cochrane collaboration's handbook. These studies had low-risk of bias for random sequence generation,

Table 2
Six studies were finally included in our meta-analysis.

Reference	Study design	Intervention	Treatment timing	Number of patients (Intervention/ control)	OP	Outcome measurements	Transfusion indication	Time and number of Hgb measurements
Park et al (2021) ^[14]	Retrospective (pro- pensity score matching)	FCM 1000mg	1 h after OP	231/231	Primary unilat- eral TKA	Hgb Post OP transfu- sion rate	Hgb < 8 g/dL or acute anemia symptoms	Pre OP POW 5
Yoo et al (2021) ^[15]	RCT	Iron isomaltoside	Intra OP	44/45	Primary unilat- eral TKA	Hgb Post OP transfu- sion rate	Hgb < 8 g/dL or acute anemia symptoms	Pre OP POD 30
Park et al (2022) ^[6]	Retrospective	FCM 1000mg	1 h after OP	78/53	Staged bilateral TKA (1 week interval)	Hgb Post OP transfu- sion rate	Hgb < 8 g/dL or acute anemia symptoms	Pre OP POW 5
Maniar et al (2022) ^[13]	Retrospective	FCM 500mg	1 d after OP	157/106	Primary unilat-	Hgb	, ,	Pre OP POW 5 (+1)
Choi et al (2022) ^[5]	RCT	FCM 1000mg (body weight ≥ 50 kg) FCM 500mg (body weight < 50 kg)	3 d after OP	54/55	Primary unilat- eral TKA	Hgb Post OP transfu- sion rate	Hgb < 7g/dL or acute anemia symptoms	Pre OP POW 4 POW 8
Lee et al (2023) ^[12]	Retrospective	Iron isomaltoside 400 mg	2 h after OP	220/198	Staged bilateral TKA (1 week interval)	Hgb Post OP transfu- sion rate	Iron group: Abnormal vital signs Non-Iron group: Low Hgb	Pre OP POW 6

FCM = ferric carboxymaltose, Hgb = hemoglobin, OP = operation, POD = post operative day, POW = post operative week, TKA = total knee arthroplasty.

Table 3

Quality assessment using Newcastle-Ottawa quality assessment scale and Cochrane collaboration's handbook.

			Selection			Comparability	Exposure					
	Quality criteria	Is case definition adequate?	Representativeness of the cases	Selection of controls	Definition of controls	Comparability on basis of design or analysis	Ascertainment of exposure Same method o ascertainment for cases and control		Nonresponse rate	Total		
Case- Control	Park et al (2021) ^{14]}	*	*	*	*	**	*	*	☆	8		
Studies	Park et al (2022) ^[6]	*	*	*	*	**	*	*	☆	8		
	Maniar et al (2022) ^[13]	*	*	*	*	**	*	*	☆	8		
	Lee et al (2023) ^[12]	*	*	*	*	**	*	*	☆	8		
RCT	Quality criteria	Random s	sequence generation	Allocation concealment		Blinding of partic- ipants	Incomplete	e outcome data	Selective repo	rting		
	Yoo et al (2021) ^[15]		Low-risk	low-risk		Low-risk	Low-risk		Low-risk			
	Choi et al (2022) ^[5]		Low-risk	Uncle	ar risk	Low-risk	Low-risk		Low-risk			

allocation concealment, blinding of participants, incomplete outcome data and selective reporting.

3.3. Meta-analysis results

In performing meta-analysis, a fixed effect model was used when the *P* value was > .05 as a result of the homogeneity test, and a random effect model was used when the *P* value was < .05.

Mean difference and 95% confidence interval were presented in the forest plot for change in hemoglobin from pre-operation to 4 to 8 week between iron supplementation group and noniron supplementation group (Fig. 2). There was a statistically significant difference in the amount of change in hemoglobin between iron supplementation group and non-iron supplementation group. The effect size were -0.44 (95% CI: -0.69 to -0.19, P value < .001) in all patients. This means that the amount of change in hemoglobin were significantly reduced in the iron supplementation group than in the non-iron supplementation group. However, in the subgroup analysis, there was no statistically significant difference in the amount of change in hemoglobin between iron supplementation group and noniron supplementation group. The effect size were -0.33 (95%) CI: -1.23 to 0.56, P value = .46) in patients with preoperative anemia and -0.30 (95% CI: -0.90 to 0.30, P value = 0.32) in patients without preoperative anemia.

Odd ratio and 95% confidence interval were presented in the forest plot for post-operation transfusion between iron supplementation group and non-iron supplementation group (Fig. 3). There was a statistically significant difference for post-operative transfusion rate between 2 groups. The effect size were 0.28 (95% CI: 0.10–0.81, *P* value = .02) in all patients. This means that the post-operative transfusion rate was significantly less in

the iron supplementation group than in the non-iron supplementation group. In the subgroup analysis, there was statistically significant difference for post-operative transfusion rate between 2 groups. The effect size were 0.34 (95% CI: 0.16–0.71, *P* value = .004) in patients with preoperative anemia, 0.06 (95% CI: 0.03–0.13, *P* value < .001) in patients without preoperative anemia and 0.13 (95% CI: 0.08–0.21, *P* value < .001) in patients with staged bilateral TKA operation.

3.4. Sensitivity analysis

For change in hemoglobin from pre-operation to 4 to 8 week, the RMSE were calculated as 0.055 in all patients, 0.471 in patients with preoperative anemia and 0.139 in patients without preoperative anemia. For post-operation transfusion, the RMSE were calculated as 0.076 in all patients, 0.077 in patients with preoperative anemia, 0.058 in patients without preoperative anemia. RMSE were not calculated when there were only 2 studies. RMSE values in all cases were calculated to be < 0.5. It can be seen that the overall effect size is not sensitive depending on the study.

3.5. Publication bias

On the basis of a few distinct methods, 2 of the authors (W.K.C. and S.G.K.) individually assessed the publication bias. The publication bias was determined using a funnel plot and the Egger test. A funnel plot was produced to investigate the risk of publication bias. All funnel plots seemed to be symmetrical (Fig. 4). In addition, the publication bias was quantified using Egger test. The *P* value of Egger test were .774 for change in hemoglobin from pre-operation

A Change in haemoglobin from pre-operation to 4-8 week in all patients.

	Iron supplementation			Non-Iron s	upplement	tation		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Adit 2002	0.76	0.78	157	1.25	0.76	106	16.5%	-0.49 [-0.68, -0.30]	
Choi 2022	-0.3	1.05	55	0.4	0.85	55	13.3%	-0.70 [-1.06, -0.34]	
Choi 2022	0.3	0.95	55	0.9	0.85	55	13.7%	-0.60 [-0.94, -0.26]	
Lee 2023	1	1.4	220	1	0.9	198	15.9%	0.00 [-0.22, 0.22]	+
Park 2021	0.42	0.85	78	0.85	1.29	53	12.5%	-0.43 [-0.83, -0.03]	
Park 2022	0	1.14	231	0.8	1.13	231	16.2%	-0.80 [-1.01, -0.59]	
Yoo 2022	0.9	1.02	44	0.9	1.05	45	11.8%	0.00 [-0.43, 0.43]	
Total (95% CI)			840			743	100.0%	-0.44 [-0.69, -0.19]	
Heterogeneity: $Tau^2 = 0.09$; $Chi^2 = 33.55$, $df = 6$ (P < 0.00001); $I^2 = 82\%$ Test for overall effect: $Z = 3.45$ (P = 0.0006)								-	ron supplementation

B Change in haemoglobin from pre-operation to 4-8 week in patients with pre-operative anemia.

	Iron sup	pplementation Non-Iron supplementation				tation		Mean Difference		Me	an Differenc	ce	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI		IV, R	tandom, 95%	6 CI	
Lee 2023	0.1	1.1	50	0.6	0.9	42	43.7%	-0.50 [-0.91, -0.09]			-		
Park 2022	-0.69	1.54	70	0.34	1.59	70	41.4%	-1.03 [-1.55, -0.51]		-	-		
Yoo 2022	2.17	1.85	6	0.1	1.86	9	15.0%	2.07 [0.15, 3.99]				•	
Total (95% CI)			126			121	100.0%	-0.33 [-1.23, 0.56]		-			
_ ,	Heterogeneity: Tau ² = 0.43; Chi ² = 10.31, df = 2 (P = 0.006); i ² = 81% Test for overall effect: Z = 0.73 (P = 0.46)									-2	-	2	4
restion overall ellect.					Iron supplement	ation Non-I	ron supplem	entation					

Change in haemoglobin from pre-operation to 4-8 week in patients without pre-operative anemia.




Figure 2. Forest plots for change in hemoglobin from pre-operation to 4–8 week between iron supplementation group and non-iron supplementation group (A) in all patients, (B) in patients with anemia, and (C) in patients without anemia.

A post-operative transfusion in all patients.

	Iron suppleme	ntation	on Non-Iron supplementation			Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
Choi 2022	7	54	6	55	19.7%	1.22 [0.38, 3.89]	
Lee 2023	129	220	191	198	22.5%	0.05 [0.02, 0.12]	
Park 2021	17	78	25	53	22.8%	0.31 [0.15, 0.67]	
Park 2022	12	231	31	231	23.3%	0.35 [0.18, 0.71]	
Yoo 2022	1	44	3	45	11.6%	0.33 [0.03, 3.26]	•
Total (95% CI)		627		582	100.0%	0.28 [0.10, 0.81]	-
Total events	166		256				
Heterogeneity: Tau ² =	: 1.12; Chi ² = 24.1	1, df = 4	(P < 0.0001); I ² = 83%				0.01 0.1 1 10 100
Test for overall effect:	Z = 2.35 (P = 0.0	2)					Iron supplementation Non-Iron supplementation

B post-operative transfusion in patients with pre-operative anemia.

	Iron supplementation Non-Iron supplementation Odds Ratio					Odd	s Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fix	ced, 95% CI		
Lee 2023	41	50	41	42	30.3%	0.11 [0.01, 0.92]		-	-		
Park 2022	10	70	20	70	64.7%	0.42 [0.18, 0.97]			\dashv		
Yoo 2022	1	6	2	9	5.0%	0.70 [0.05, 10.01]		•		_	
Total (95% CI)		126		121	100.0%	0.34 [0.16, 0.71]		•			
Total events	52		63								
Heterogeneity: Chi² =		0%				0.01	0.1	1	10	100	
Test for overall effect:	U4)						Iron supplementatio	n Non-Iron su	pplement	ation	

C post-operative transfusion in patients without pre-operative anemia.

	Iron supplementation		Non-Iron supplem	entation		Odds Ratio	Odds Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI			
Lee 2023	88	170	150	156	85.9%	0.04 [0.02, 0.10]	———			
Park 2022	2	161	11	161	12.4%	0.17 [0.04, 0.79]				
Yoo 2022	0	38	1	36	1.7%	0.31 [0.01, 7.79]	· ·			
Total (95% CI)		369		353	100.0%	0.06 [0.03, 0.13]	•			
Total events	90		162							
Heterogeneity: Chi ² =	3.33, $df = 2$ ($P = 0$	0.19); I ² =	40%				0.01 0.1 1 10 100			
Test for overall effect:	Z = 7.45 (P < 0.0)	0001)					Iron supplementation Non-Iron supplementation			

D post-operative transfusion in patients with staged bilateral TKA operation.

	Iron supplementation Non-Iron supplementation					Odds Ratio	Odds	Odds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixe	M-H, Fixed, 95% CI		
Lee 2023	129	220	191	198	73.9%	0.05 [0.02, 0.12]				
Park 2022	12	231	31	231	26.1%	0.35 [0.18, 0.71]				
Total (95% CI)		451		429	100.0%	0.13 [0.08, 0.21]	•			
Total events	141		222							
Heterogeneity: Chi²=	13.01, df = 1 (P =	0.0003);	I ² = 92%				0.01 0.1	1 10	100	
Test for overall effect:					Favours [experimental]		100			

Figure 3. Forest plots for post-operative transfusion between iron supplementation group and non-iron supplementation group (A) in all patients, (B) in patients with anemia, (C) in patients without anemia, and (D) in patients with staged bilateral TKA operation. TKA = total knee arthroplasty.

to 4 to 8 week and 0.192 for post-operative transfusion. Therefore, statistically significant publication bias was unlikely to occur.

4. Discussion

Meta-analyses on the effects of intraoperative or postoperative administration of IV iron supplements during orthopedic surgery, including TKA, have been previously published.^[16-18] However, most of these studies included not only TKA but also other hip joint surgeries, such as hip arthroplasty or hip fracture.^[19] Additionally, previous meta-analyses analyzed studies that included various time points for IV iron supplementation, including preoperative, intraoperative, and postoperative administration.^[16,17] Generally, it is known that hemoglobin recovery takes about 2 weeks after IV iron supplementation, therefore preoperative administration of IV iron supplements in outpatient setting is commonly considered effective.^[9] However, due to practical limitations in additional outpatient visits for IV iron supplementation, recent practice has seen an increase in intraoperative or postoperative administration of IV iron supplements in patients undergoing TKA. For this reason, the

authors of this study aimed to analyze the effects of intraoperative or postoperative IV iron supplementation, excluding preoperative administration, in patients undergoing primary TKA.

perative administration, in patients undergoing primary 1KA.

The following are the findings revealed through the analysis:

First, in patients undergoing primary TKA, the administration of IV iron supplements during or after surgery showed faster hemoglobin recovery between 4 and 8 weeks after surgery compared to the group without IV iron supplementation. This period, 4 and 8 weeks after surgery, is characterized by rehabilitation for improved knee movement and recovery of decreased muscle strength. Rapid hemoglobin recovery after surgery is known to aid in functional recovery and reduce the length of hospital stay. [20,21] Additionally, rapid hemoglobin recovery after surgery promotes general well-being, facilitating wound healing and early rehabilitation. [18]

Second, in patients undergoing primary TKA, the group receiving intraoperative or postoperative IV iron supplementation showed a lower frequency of allogeneic blood transfusion after surgery compared to the control group. Previous studies have reported adverse effects associated with allogeneic blood transfusion after TKA, including impaired functional recovery

Figure 4. Funnel plots for (A) change in hemoglobin from pre-operation to 4–8 week and (B) post-operative transfusion between iron supplementation group and non-iron supplementation group.

and increased risk of infection. [22,23] Ryan et al [24] found that a hemoglobin level below 12.5 g/dL has increased the risk of allogeneic blood transfusion after TKA. Pierson et al^[25] reported an average decrease of 3.8 g/dL in hemoglobin levels after TKA. In this study, the analysis was based on a transfusion threshold of hemoglobin levels below 8 g/dL or 7 g/dL. Therefore, patients with hemoglobin levels below 12.5 g/dL, as suggested by Ryan et al, would require allogeneic blood transfusion in the absence of specific measures to improve hemoglobin recovery. The subjects of the 6 studies included in the analysis were all patients undergoing total knee arthroplasty, regardless of the presence or absence of anemia. Considering that surgical inflammation caused by TKA induces functional iron deficiency, [26] which is mediated by increased hepcidin during the postoperative period, [27] even patients without preoperative anemia may experience a decrease in hemoglobin levels due to the substantial blood loss and increased hepcidin levels after TKA. Therefore, analyzing the decrease in hemoglobin levels in all patients, regardless of preoperative anemia, is appropriate.

Among the 6 studies included in the analysis, 2 studies investigated staged TKA instead of unilateral TKA. In both studies, bilateral TKA was performed sequentially with a 1-week interval. Considering the time required for hemoglobin recovery after surgery, sequential bilateral TKA with a 1-week interval carries a higher risk of blood transfusion during the hospital stay compared to unilateral TKA. The analysis of the 2 studies on sequential bilateral TKA demonstrated a statistically significant lower frequency of allogeneic blood transfusion in the group receiving intraoperative or postoperative IV iron supplementation.

The limitations of this study are as follows: First, there were variations in the composition and dosage of IV iron supplements used in the studies. Secondly, different indications for blood transfusion were applied in each facilities. Thirdly, 2 out of the 6 studies included in the analysis involved sequential bilateral TKA with a 1-week interval.

5. Conclusion

The administration of IV iron supplements during or after TKA surgery increases hemoglobin recovery between 4 and 8 weeks after surgery and reduces the need for allogeneic blood transfusion during hospitalization.

Author contributions

Conceptualization: Jin Woo Bae, Dong Jin Bae, Dong Kun Kim, Won Kee Choi.

Data curation: Jae Bum Kwon, Jin Woo Bae, Won Kee Choi.

Formal analysis: Sang Gyu Kwak, Dong Kun Kim, Won Kee

Funding acquisition: Dong Kun Kim, Won Kee Choi.

Investigation: Jae Bum Kwon, Dong Jin Bae, Dong Kun Kim, Won Kee Choi.

Methodology: Jin Woo Bae, Won Kee Choi.

Project administration: Won Kee Choi.

Resources: Won Kee Choi.

Software: Won Kee Choi.

Supervision: Sang Gyu Kwak, Won Kee Choi.

Validation: Jin Woo Bae, Won Kee Choi.

Visualization: Jin Woo Bae, Dong Kun Kim, Won Kee Choi.

Writing – original draft: Sang Gyu Kwak, Jae Bum Kwon, Dong Jin Bae, Dong Kun Kim, Won Kee Choi

Writing – review & editing: Won Kee Choi.

References

- [1] Khanasuk Y, Ngarmukos S, Tanavalee A. Does the intramedullary femoral canal plug reduce blood loss during total knee arthroplasty? Knee Surg Relat Res. 2022;34:31.
- [2] Kimball CC, Nichols CI, Vose JG. Blood transfusion trends in primary and revision total joint arthroplasty: recent declines are not shared equally. J Am Acad Orthop Surg. 2019;27:e920–7.
- [3] Spahn DR, Moch H, Hofmann A, et al. Patient blood management: the pragmatic solution for the problems with blood transfusions. Anesthesiology. 2008;109:951–3.
- [4] Munoz M, Franchini M, Liumbruno GM. The post-operative management of anaemia: more efforts are needed. Blood Transfus. 2018;16:324–5.
- [5] Choi KY, Koh IJ, Kim MS, et al. Intravenous ferric carboxymaltose improves response to postoperative anemia following total knee arthroplasty: a prospective randomized controlled trial in Asian cohort. I Clin Med. 2022:11:2357.
- [6] Park HS, Bin SI, Kim HJ, et al. Immediate intravenous iron administration improves anaemia recovery following total knee arthroplasty: a propensity-matched analysis. Vox Sang. 2022;117:243–50.
- [7] Khalafallah AA, Yan C, Al-Badri R, et al. Intravenous ferric carboxy-maltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomised controlled trial. Lancet Haematol. 2016;3:e415–25.
- [8] Bisbe E, Molto L, Arroyo R, et al. Randomized trial comparing ferric carboxymaltose vs oral ferrous glycine sulphate for postoperative anaemia after total knee arthroplasty. Br J Anaesth. 2014;113:402–9.
- [9] Alleyne M, Horne MK, Miller JL. Individualized treatment for iron-deficiency anemia in adults. Am J Med. 2008;121:943–8.
- [10] Smith A, Moon T, Pak T, et al. Preoperative anemia treatment with intravenous iron in patients undergoing major orthopedic surgery: a systematic review. Geriatr Orthop Surg Rehabil. 2020;11:2151459320935094.
- [11] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5.

- [12] Lee SS, Lee J, Moon YW. Efficacy of immediate postoperative intravenous iron supplementation after staged bilateral total knee arthroplasty. BMC Musculoskelet Disord. 2023;24:17.
- [13] Maniar AR, Mishra A, Sanghavi N, et al. Does postoperative intravenous ferric carboxymaltose hasten the recovery of hemoglobin in patients post total knee arthroplasty? J Arthroplasty. 2022;37:S155-8.
- [14] Park HS, Bin SI, Kim HJ, et al. Short-term high-dose intravenous iron reduced peri-operative transfusion after staggered bilateral total knee arthroplasty: a retrospective cohort study. Vox Sang. 2022;117:562–9.
- [15] Yoo S, Bae J, Ro DH, et al. Efficacy of intra-operative administration of iron isomaltoside for preventing postoperative anaemia after total knee arthroplasty: a randomised controlled trial. Eur J Anaesthesiol. 2021;38:358–65.
- [16] Koo CH, Shin HJ, Cho H, et al. The effect of perioperative intravenous iron on hemoglobin in surgical patients: a meta-analysis. J Surg Res. 2020;246:42–51.
- [17] Shin HW, Park JJ, Kim HJ, et al. Efficacy of perioperative intravenous iron therapy for transfusion in orthopedic surgery: a systematic review and meta-analysis. PLoS One. 2019;14:e0215427.
- [18] Yang Y, Li H, Li B, et al. Efficacy and safety of iron supplementation for the elderly patients undergoing hip or knee surgery: a meta-analysis of randomized controlled trials. J Surg Res. 2011;171:e201–7.

- [19] Lee SH, Kim JI, Choi W, et al. Effectiveness of iron supplementation in the perioperative management of total knee arthroplasty: a systematic review. Knee Surg Relat Res. 2020;32:44.
- [20] Liu D, Dan M, Martinez Martos S, et al. Blood management strategies in total knee arthroplasty. Knee Surg Relat Res. 2016;28:179–87.
- [21] Kim SK, Seo WY, Kim HJ, et al. Postoperative intravenous ferric carboxymaltose reduces transfusion amounts after orthopedic hip surgery. Clin Orthop Surg. 2018;10:20–5.
- [22] Hart A, Khalil JA, Carli A, et al. Blood transfusion in primary total hip and knee arthroplasty Incidence, risk factors, and thirty-day complication rates. J Bone Joint Surg Am. 2014;96:1945–51.
- [23] Kim JL, Park JH, Han SB, et al. Allogeneic blood transfusion is a significant risk factor for surgical-site infection following total hip and knee arthroplasty: a meta-analysis. J Arthroplasty. 2017;32:320–5.
- [24] Ryan SP, Klement MR, Green CL, et al. Preoperative hemoglobin predicts postoperative transfusion despite antifibrinolytics during total knee arthroplasty. Orthopedics. 2019;42:103–9.
- [25] Pierson JL, Hannon TJ, Earles DR. A blood-conservation algorithm to reduce blood transfusions after total hip and knee arthroplasty. J Bone Joint Surg Am. 2004;86:1512–8.
- [26] van Iperen CE, Kraaijenhagen RJ, Biesma DH, et al. Iron metabolism and erythropoiesis after surgery. Br J Surg. 1998;85:41–5.
- [27] Munoz M, Acheson AG, Auerbach M, et al. International consensus statement on the peri-operative management of anaemia and iron deficiency. Anaesthesia. 2017;72:233–47.